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Abstract
Background: To overcome the problem of increasing drug resistance, traditional medicines are an important
source for potential new anti-malarials. Caesalpinia pluviosa, commonly named “sibipiruna”, originates from Brazil
and possess multiple therapeutic properties, including anti-malarial activity.
Methods: Crude extract (CE) was obtained from stem bark by purification using different solvents, resulting in
seven fractions. An MTT assay was performed to evaluate cytotoxicity in MCF-7 cells. The CE and its fractions were
tested in vitro against chloroquine-sensitive (3D7) and -resistant (S20) strains of Plasmodium falciparum and in vivo
in Plasmodium chabaudi-infected mice. In vitro interaction with artesunate and the active C. pluviosa fractions was
assessed, and mass spectrometry analyses were conducted.
Results: At non-toxic concentrations, the 100% ethanolic (F4) and 50% methanolic (F5) fractions possessed
significant anti-malarial activity against both 3D7 and S20 strains. Drug interaction assays with artesunate showed a
synergistic interaction with the F4. Four days of treatment with this fraction significantly inhibited parasitaemia in
mice in a dose-dependent manner. Mass spectrometry analyses revealed the presence of an ion corresponding to
m/z 303.0450, suggesting the presence of quercetin. However, a second set of analyses, with a quercetin standard,
showed distinct ions of m/z 137 and 153.
Conclusions: The findings show that the F4 fraction of C. pluviosa exhibits anti-malarial activity in vitro at non-toxic
concentrations, which was potentiated in the presence of artesunate. Moreover, this anti-malarial activity was also
sustained in vivo after treatment of infected mice. Finally, mass spectrometry analyses suggest that a new
compound, most likely an isomer of quercetin, is responsible for the anti-malarial activity of the F4.
Background
One of the principal reasons for malaria’sh i g hm o r b i d -
ity and mortality is the widespread presence of drug-
resistant strains of the parasite, resulting in the dramati-
cally decreased efficacy of the available anti-malarial
drugs, such as chloroquine (CQ) and sulphadoxine-pyri-
methamine (SP) [1].
The compounds most widely used to treat malaria,
quinine and artemisinin, are derived from traditional
medicine and plant extracts [2]. Quinine was the first
drug successfully used to treat malaria. However, this
alkaloid has a high level of toxicity and a short pharma-
cological half-life, which limit its use [2,3]. Currently,
artemisinin-based combination treatment (ACT) is the
therapy of choice for uncomplicated Plasmodium falci-
parum malaria in areas of widespread parasite CQ-resis-
tance [4]. However, failure to clear parasites after ACT
treatment has recently been reported on the Cambodia-
Thailand border, and genes related to artemisinin resis-
tance have been discovered [5-9]. Furthermore, no new
class of anti-malarial has been introduced since 1996
[10], and the most successful malaria vaccine was only
partially efficient and short lived [11]. Therefore, the dis-
covery of new potential anti-malarial compounds is
urgently needed.
Caesalpinia pluviosa, commonly named “sibipiruna”,
is a leguminous of the Fabaceae family that is originated
from Brazil. This genus is a rich source of furanoditer-
penoids and has demonstrated multiple therapeutic
properties, including antiviral [12-14], antimicrobial
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[19,20] activities. Preliminary studies have shown that C.
pluviosa crude extract (CE) had in vitro anti-malarial
activity against a CQ-resistant strain [21]. However, that
work focused only on the CE, and no parasite inhibition
was observed in an in vivo test. In the present study, the
in vitro anti-malarial activities of C. pluviosa extracts
and the fractions effective against CQ- resistant and
-sensitive P. falciparum strains, alone or in combination
with artesunate, have been evaluated and identified.
The cytotoxic properties of these plant-derived materi-
als were determined and the in vivo effects in Plasmo-
dium chabaudi-infected mice were also studied. Finally,
mass spectrometry analyses were carried out to charac-
terize new potential molecules with anti-malarial
activity.
Methods
Plant extraction and fractionation
Stem bark from C. pluviosa was collected and deposited
at the campus of Universidade Estadual de Maringá,
Brazil, in September 2006 as voucher #HUEM 12492.
All plant material was ground and subjected to a turbo-
extraction process with 50% ethanol-water for 15 min at
a T<40°C. After evaporation of the organic solvent using
a rotavapor under reduced pressure at 40°C, the CE (50
g) was lyophilized. CE was dissolved in water (500 mL)
and extracted with ethyl acetate (10 × 500 mL). After
removing the organic solvents by rotavapor under
reduced pressure, aqueous (F1) and ethyl acetate (F2)
fractions were formed. The F2 fraction was chromato-
graphed by CC (chromatographic column) on Sephadex
LH-20, resulting in five sub-fractions: 50% ethanolic-
water (F3; 2.17 g), 100% ethanolic (F4; 0.21 g), 50%
methanolic-water (F5; 0.06 g), 100% methanolic (F6;
0.17 g) and 70% acetone-water (F7; 0.08 g). All fractions
were concentrated under reduced pressure at 40°C for
solvent evaporation. These samples were lyophilized and
used in biological tests, as described below. Concentra-
tions of C. pluviosa CE/fractions were calculated on a
dry material basis. Figure 1 summarizes the C. pluviosa
extraction and its fractionation process.
Cultivation of Plasmodium falciparum infected-
erythrocytes P. falciparum
Plasmodium falciparum chloroquine-sensitive (3D7) [22]
and chloroquine-resistant (S20) [23] strains were cul-
tured in a candle jar as described elsewhere [24]. Briefly,
P. falciparum infected-erythrocytes (Pf-iE) were culti-
vated in fresh-type O
+ human erythrocytes (UNICAMP,
Blood Bank, Brazil) suspended at 4% final haematocrit
in complete medium (RPMPI-1640 containing 10%
homologous human plasma and 25 mM HEPES buffer,
pH 7.4).
Cytotoxicity assays
The cytotoxicities of the plant CE/fractions were
assessed by MTT assay [3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide] to evaluate their effects
on the proliferation of a human breast cancer cell line,
MCF-7 [25,26]. Cells were cultivated in DMEM/HAM-
F12 medium supplemented with 10% heat-inactivated
foetal bovine serum, penicillin (1 unit/mL) and strepto-
mycin (1 unit/mL) in a humidified atmosphere of 5%
CO2 at 37°C. MCF-7 cells were seeded in 96-well plates
at a density of 2 × 10
4 cells per well and incubated with
different concentrations of plant samples. After 48 h, 5
mg/mL of MTT solution was added for 4 h and forma-
zan crystals were resuspended in 50 μL of isopropanol.
The absorbances (A590) of cells containing medium
(control) or in the presence of different concentrations
of the CE/fractions (tested) were determined using an
ELISA reader (Asys-Expertplus, UK). Data were calcu-
lated as the percentage of inhibition using the following
formula: % inhibition = [1 - (At/Ac)] × 100. At and Ac
refer to the absorbance of the tested C. pluviosa CE/
fractions and the control, respectively.
The toxicity of the C. pluviosa CE/fractions was also
determined in non-infected erythrocytes (niE) in the
presence of different plant sample concentrations or
untreated cells (control). The niE were cultured in com-
plete medium at 37°C in candle jars, and the red blood
cell density (RBCD) was determined after 48 h incuba-
tion with the aid of a Neubauer chamber. The percen-
tage of RBCD, relative to 0 h, was calculated by the
following formula: % RBCD = [1 - (n° niE treated with
CE and fractions per hour after incubation/n° niE per or
at 0 h)] × 100. Non-toxic samples were those in which
no significant inhibition on MCF-7 growth or RBCD,
relative to the control, was observed.
In vitro anti-malarial activity of C. pluviosa extract and its
fractions
[
3H] hypoxanthine incorporation assays were used to
determine C. pluviosa anti-malarial activity against Pf-iE
growth as previously described [27]. Background values
were determined by incubation with niE. Parasite growth
in the presence of C. pluviosa extract and fractions (sam-
ple) was compared to control cultures (medium only).
Inhibition of parasite growth was calculated according to
the following formula: % inhibition = [1 - (n° niE treated
with CE and fractions per hour after incubation/n° niE per
or at 0 h)] × 100. The anti-malarial activities of the CE/
fractions were classified according to their IC50 (μg/mL)
values, defined as that concentration of compound which
inhibits growth by 50% relative to untreated controls [21].
Fractions of IC50 < 5 were considered active, fractions of
10 > IC50 > 5 represented moderate activity and fractions
with IC50 values > 10 were classified as inactive.
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In vivo anti-malarial activity of plant fractions was veri-
fied in C57BL/6 mice (7-10 weeks-old, weighing 20 ± 3
g) purchased from the Centro de Bioterismo-UNI-
CAMP, Brazil, and maintained in specific pathogen-free
animal facility. All experiments and procedures were
approved by the UNICAMP Ethical Committee for Ani-
mal Research (protocol # 1806-1). Groups of 10 mice
were infected intraperitoneally (i.p) with 10
6 iE of P.
chabaudi chabaudi AS (PchAS). PchAs is a non-lethal
strain kindly provided by Hernando Del Portillo
(Department of Parasitology, ICB, USP, São Paulo-SP,
Brazil and currently at CRESIB, Barcelona, Spain). One
hour post-infection (p.i), groups of 10 animals were
injected i.p with different concentrations (75, 50, 25 mg/
kg/day) of the F4 and F5 fractions (50, 25 mg/kg/day)
diluted in 200 μL PBS with 1.25% DMSO. Mice were
treated for 4 days (day 0-3 p.i) according to previous
studies [28,29]. Parasitaemia was monitored daily by
microscopic examination of Giemsa-stained thin blood
smears prepared from mouse tail blood beginning on
the third day p.i. Mice in the control group received 200
μL of 1.25% DMSO diluted in PBS.
In vitro compounds interaction on the Pf-iE
The artesunic acid (artesunate) used for combined treat-
ment with F4 fractions was derived from artemisinin
isolated from 1 kg of dried-plant material collected from
CPQBA’s experimental field (hybrid Ch × Viet 55) and
extracted with ethanol as previously described [30]. Sub-
sequent semi-synthesis procedures provided pure artesu-
nic acid (98%), which was further dissolved in sodium
bicarbonate solution (0.5%) prior to use as sodium arte-
sunate on Pf-iE. Artesunate was identified by comparing
the experimental product to a commercial sample
(Aldrich
® 98%, Sigma-Aldrich, USA). The 3D7 and S20
strains of P. falciparum (4% parasitaemia and 2% hae-
matocrit) were incubated for 48 h in the presence of
artesunate and the F4 fraction, solubilized in 1.25%
DMSO. C. pluviosa fractions were dispensed into the
96-well micro-titre plates at different concentration (ng/
mL) combinations of the F4 fraction and artesunate as
Figure 1 Schematic view of the extraction and fractionation of Caesalpinia pluviosa.
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combination was performed by adding 50 μLo fC. plu-
viosa fraction (4000 ng/mL) to 50 μL artesunate (1.8 ng/
mL) and so on. Parasitaemia was analysed in thin blood
smears, and the inhibition was compared to that of the
control (100 μL of 1.25% DMSO) that represented 100%
of Pf-iE growth. Corresponding IC50 values were deter-
mined for each drug alone and in combination [31].
The synergism degree was evaluated as described pre-
viously [32]. The sum of fractional inhibition concentra-
tion (SFIC) was calculated using the formula: K = Ac/Ae
+B c/Be, where K is the value corresponding to SFIC, Ac
and Bc are the equally effective concentrations (IC50)
when used in combination, and Ae and Be are the
equally effective concentrations used alone. The in vitro
drug interaction was classified as follows: SFIC < 1
denotes synergism, 1 < SFIC < 2 denotes additive inter-
action, and SFIC≥2 denotes antagonism [33].
Mass spectrometry
Samples of the F4 fraction were dissolved in HPLC
grade MeOH, and 10 μL of this solution was diluted in
1m Lo fs o l v e n t( M e O H / H 2O [1:1] with 0.1% formic
acid [v/v]). A Q-TOF mass spectrometer (Micromass,
Manchester, UK) with an electrospray source was used
to perform Electrospray Ionization/Mass Spectrometry
(ESI-MS) and ESI-MS/MS analyses. The mass spectro-
meter was operated in the positive ion mode. The ESI
source unit was operated at a desolvation temperature
of 100°C, with a capillary voltage of 3.5 kV and cone
voltage of 40 eV. Samples were directly infused at a rate
of 10 μL min
-1 into the ion source using a syringe pump
(Pump 11, Harvard Apparatus, Holliston, USA). The
spectra were acquired in the interval of 100 to 2000 m/z
and accumulated for 1 min. ESI-MS/MS were obtained
for ions of interest using collision energies ranging from
10 to 50 eV. The collision gas pressure (argon) was opti-
mized to produce extensive fragmentation of the ions
under investigation. To calculate the theoretical masses
of the compounds, MassLynx 4.1 software was used.
The error among the theoretical and experimental
masses was calculated according to the following for-
mula: E = (mex -m t/mt)×1 0
6;w h e r em ex is an experi-
mental mass and mt is a theoretical mass.
Statistical analysis
Toxicity data were analysed using ANOVA or Mann-
Whitney tests. Statistical significance between treated
and non-treated P. falciparum-infected erythrocytes was
determined using the Mann-Whitney U test. The inhibi-
tion of parasitaemia, resulting from sole or combined
treatment with artesunate and F4, was compared using
the Kruskal-Wallis test. For analysis of in vivo treatment
with the F4 fraction, an ANOVA test was used.
Calculations were performed using BioEstat™ version
3.0 (CNPq, Brazil), and values were considered signifi-
cant when p < 0.05.
Results
Cytotoxicity assessment of C. pluviosa
The cytotoxic potential of the CE and fractions (F1-F7)
was determined on MCF-7 cells by means of MTT
assays. As shown in Table 1, plant CE from all fractions
was highly cytotoxic at concentrations of 1600 and 400
μg/mL, significantly inhibiting cell growth from 20%
(F4) to 66% (F6) (p < 0.05). In contrast, at 100 μg/mL
the F4 and the F7 fractions did not significantly reduce
cell growth compared to the control. The F1 and F5
fractions slightly, but significantly, inhibited MCF-7 cell
development. No inhibition was observed by 25 μg/mL
of any fraction. To determine if this low toxicity could
be extant to niE, the RBCD percentage of plant CE and
fractions relative to the control was determined at con-
centrations varying from 0.19 to 25 μg/mL.
In vitro determination of C. pluviosa anti-malarial activity
To evaluate the anti-malarial effects of plant CE/frac-
tions against chloroquine-sensitive (3D7) and -resistant
(S20) P. falciparum strains, parasite growth inhibition
was measured by determining [
3H] hypoxanthine incor-
poration at different concentrations (0.19 - 25 μg/mL).
The anti-malarial activity IC50 values were compared for
C. pluviosa CE and fractions. As shown in Table 2 and
consistent with a previous study [21], the F1 and the F7
fractions were inactive (> 10 μg/mL) against both strains
of parasites. However, the IC50 values of the CE and the
other fractions were < 5 μg/mL, indicating inhibition
activity. Of these, the F3 fraction and the CE presented
higher IC50 values than the F4 and F5 fractions.
The inhibition curve of the CE and the fractions that
presented anti-malarial activity (IC50 <5μg/mL) are
shown in Figure 2(A-D). The CE and the F2, F4 and F5
Table 1 Growth inhibition (%)
a of MCF-7 cells in vitro
treatment of Caesalpinia pluviosa assessed by MTT assay.
Concentrations (μg/mL)
Samples 1600 400 100 25
CE 33.13 ± 10.88* 26.42 ± 19.26 21.95 ± 14.06 NT
a
F1 45.43 ± 5.60* 44.21 ± 8.48* 6.98 ± 6.11 NT
F2 50.81 ± 13.25* 27.98 ± 7.15* 18.83 ± 17.15 NT
F3 41.67 ± 10.26* 44.31 ± 13.98* 45.73 ± 6.88* NT
F4 55.90 ± 9.37* 20.19 ± 3.38* NT NT
F5 46.98 ± 11.73* 37.85 ± 7.86* 8.28 ± 2.56* NT
F6 66.25 ± 5.45* 53.82 ± 4.69* 17.39 ± 14.27 NT
F7 62.66 ± 9.91* 44.93 ± 18.61* NT NT
aValues are expressed as the mean of triplicates ± SD.
bNT: Non toxic.
*p < 0.05
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parasite strains in a dose-dependent manner. The CE
and all three fractions inhibited parasite development at
concentrations of 25 and 12.5 μg/mL. At 6.25 μg/mL,
inhibition was observed in the fractionated, but not
crude extract. Notably, only the F4 fraction was able to
sustain the inhibition on parasite growth throughout
several concentrations, as shown in Figure 2C.
Evaluation of the in vivo anti-malarial activity of C.
pluviosa
After demonstrating the capacity of F4 and F5 fractions
to control parasite burden in vitro, we evaluated
whether this activity could be sustained in a mouse
model of infection. Plasmodium chabaudi-infected mice
were treated with different concentrations of both frac-
tions for four days (day 0-3 p.i), starting at 1 h p.i. As
shown in Figure 3, the parasitaemia of infected-mice
was significantly reduced in a dose-dependent manner
when the F4 fraction was administered at doses of 50
and 25 mg/kg/day during days 5-8 p.i. The highest dose
(50 mg/kg/day) inhibited parasitaemia on days 6 and 7
p.i by 79.4% and 74.1%, respectively (Table 3). At the
lower dose of 25 mg/kg/day, a significant reduction of
parasite growth was also observed, although the percen-
tage of inhibition achieved on day 6 p.i was 63.6%
(Table 3). Doses of 75 mg/kg/day of the F4 and 50 mg/
kg/day of the F5 were fatal to 40% of animals (n = 10)
on days 2 and 4 p.i, respectively. In another set of
experiments, 50 mg/kg/day of the F4 fraction (during
days 3-7 p.i) inhibited parasite growth by 51% to 81%
(Table 3).
Table 2 C. pluviosa IC50 values (μg/mL) for crude extract
and its fractions
Plant Samples IC50 3D7 IC50 S20
CE 4.84 ± 0.17 3.41 ± 2.45
F1 10.98 ± 6.01 13.29 ± 2.70
F2 2.13 ± 0.94 2.07 ± 1.38
F3 4.55 ± 2.05 5.49 ± 1.26
F4 0.72 ± 0.29 1.25 ± 0.38
F5 0.59 ± 0.33 1.72 ± 0.27
F6 1.30 ± 0.43 3.61 ± 2.46
F7 17.19 ND
The data shown are expressed as the mean of quadruplicates ± SD.
ND: Not determined.
Figure 2 Assessment of C. pluviosa anti-malarial activity against P. falciparum. Inhibition (%) of parasite growth of chloroquine-sensitive
(3D7) and -resistant (S20) strains of P. falciparum cultivated 48 h at 37°C with C. pluviosa (A) crude extract and (B) ethyl acetate, (C) 100%
ethanolic, (D) 50% methanolic fractions. The results are expressed as the mean of quadruplicates ± SD. (*p < 0.05 vs. untreated parasites).
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artesunate
As shown in Figure 4, artesunate combined with the F4
fraction significantly reduced parasite development com-
pared to the reduction observed when either compound
was tested alone. The IC50 values (ng/mL) of the F4
fraction and artesunate alone were 3237 and 1.324,
respectively, whereas the combination of the two led to
values of 1402 and 0.630 respectively. Calculation of the
SFIC value (0.908) indicated a synergic effect of the F4
fraction with artesunate.
Molecular composition analysis of fractions from C.
pluviosa
After assessing anti-malarial activity in vitro and in vivo,
mass spectrometry was performed to characterize and
identify the possible molecules involved in the anti-
malarial activity. To accomplish this, the F4 (active) and
F7 (inactive) fractions were ionized, and their spectra
were analysed. As shown in Figure 5, their spectra dis-
played similarities, including m/z 102.1314, 150.1387,
195.0256, 288.3157 and 415.2506. However, the most
active fraction (F4) presented a distinct signal of m/z
303.0450.
As these compounds were protonated [M+H]
+,s u b -
stances with a molecular mass (MM) of 302 in Caesalpi-
nia spp. were searched, corresponding to the 303.0450.
Table 4 shows all compounds found in the literature
with 302 MM, which include ellagic acid [34], protosap-
panin C [35], sappanone B [36], 3’-deoxy-4-O-methyle-
pisappanol [36], quercetin [37], and voucapen-5a-ol
[38]. The high resolution and accuracy of mass
Figure 3 Effect of the C. pluviosa F4 fraction on murine-derived Plasmodium.G r o u p so ft e nC 5 7 B L / 6m i c ei n f e c t e di . pw i t h1 0
6 iE
Plasmodium chabaudi chabaudi were left untreated or treated with different doses of the F4 fraction administered i.p for 4 consecutive days
(days 0 to 3 p.i), starting on day 0 at 1 h p.i. The parasitaemia levels were determined daily until day 12 p.i. Results are expressed as the mean of
a group mice ± SD. (*p < 0.05 vs. untreated mice group). The administration of F4 fraction is indicated by arrows.
Table 3 Parasitemia inhibition
a of Plasmodium chabaudi-infected mice left untreated or treated with different doses
of the 100% ethanolic fraction for 4 days (0-3 post-infection) from two independent experiments
Doses
(mg/kg/day)
Days post-infection
D3 D4 D5 D6 D7 D8
Experiment
# 1 50 ND 54.22 ± 14.20* 66.72 ± 13.16* 79.44 ± 5.77* 72.17 ± 12.28* 32.74 ± 11.59*
25 ND 29.10 ± 11.51 51.46 ± 23.74* 63.64 ± 13.71* 57.45 ± 17.15* 21.50 ± 9.82*
# 2 50 81.16 ± 7.23* 90.45 ± 5.53* 91.06 ± 5.40* 86.04 ± 5.38* 51.04 ± 16.45* NI
a Values are expressed as the mean of parasitemia inhibition (%).
NI: No inhibition.
ND: Not determined.
* p < 0.05 vs. control
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masses error. After calculating the theoretical masses of
all retrieved compounds and the error among theoretical
and experimental masses, quercetin was the only com-
pound with an acceptable error (E = 18.15 ppm).
To confirm the hypothesis that quercetin was the cor-
responding molecule for the m/z 303.0450 signal found
in the F4 fraction, a new set of ESI-MS analyses using a
quercetin standard (Sigma-Aldrich, USA) and the F4
fraction was performed (Figure 6). Although both
Figure 4 Evaluation of the interaction between the F4 fraction and artesunate. Inhibition (%) of parasite development (3D7) cultivated 48
h at 37°C with different concentration (ng/mL) combinations of the F4, artesunate (AS) or as a combined solution (F4+AS). The results are
expressed as the mean of triplicates ± SD. (*p < 0.05 vs. non-combined treatment).
Figure 5 Electrospray Ionization/Mass Spectrometry (ESI-MS) analyses of the (A) 70% acetone-water and (B) 100% ethanolic fractions.
Ions are marked either as those detected in both spectra (*) or only in the F4 fraction (#).
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distinct signs of m/z 137 and 153 were observed only in
the quercetin standard.
Discussion
Medicinal plants present a promising source of novel
therapeutic agents for the treatment of many tropical
diseases, including those caused by protozoa. These data
confirmed the anti-malarial activity of the CE [21,39]
and indicate that the F4 fraction possibly contains the
main compound related to this activity.
When assessing anti-malarial activity in vitro,a sc l a s s i -
fied previously [21], the CE/fractions of C. pluviosa have
been presented inhibitory activity against chloroquine-
sensitive (3D7) and -resistant (S20) strains of P. falci-
parum. These findings differ from previous studies
[21,39], which reported that the CE is inactive against the
chloroquine-sensitive strain (IC50 =1 5μg/mL). More-
over, the anti-malarial activity of the CE found here was
twofold more efficient against the chloroquine-resistant
strain (IC50 =3 . 4 1μg/mL) when compared with that
found in the same previous studies (IC50 =8 . 3μg/mL).
The discrepancy in IC50 values might be due to differ-
ences in the phytochemical and pharmacokinetic proper-
ties of the extract, which can vary depending on the
origin, genotype and harvest period of the plants [40,41].
Because the F4 and F5 fractions presented the strongest
inhibitory activity in vitro, these two fractions were cho-
sen for evaluation in P. chabaudi-infected mice. After
Table 4 Molecular composition identified in Caesalpinia
spp
Composition Molecular formula [M+1]
+ E (ppm) References
1C 14H6O8 303.0141 101.97 [34]
2C 16H14O6 303.0869 138.24 [35]
3C 16H14O6 303.0869 138.24 [36]
4C 17H18O5 303.1233 258.31 [36]
5C 15H10O7 303.0505 18.15 [37]
6C 20H30O2 303.2324 618.01 [38]
1. Ellagic acid, 2. Protosappanin C, 3. Sapponone B, 4. 3-deoxy-4-O-
methylepisappanol, 5. Quercetin, 6. Voucapen-5a-ol. The compounds 2 and 3
are isomeric forms. Compounds with molar masses at 302 and its molecular
formula were obtained from literature. [M+1]
+, molar masses plus a proton. E:
Error between theoretical and experimental masses.
Figure 6 ESI-MS/MS of the ion of m/z 303 from the (A) 100% ethanolic fraction or from a (B) solution of quercetin standard.M a j o r
fragment ions are marked as either detectable in both spectra (*) or only the spectra of the quercetin standard (#).
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malarial activity of the F4 fraction was also very efficient
in vivo. These data show that even after the fractionation
and purification processes of the extract, no significant
anti-malarial activity modification was observed. This is
noteworthy because previous studies have reported that
certain extracts and fractions have strong activity in vitro,
but no inhibitory activity in vivo [42,43].
As ACT has been employed in areas with higher ratios
of anti-malarial treatment failure, and interaction with
artesunate has been a major step in drug discovery [44],
the anti-malarial activity of the F4 fraction in the pre-
sence of artesunate was evaluated. Although few studies
have shown in vitro synergistic interactions of natural
compounds with artesunate [45], these analyses showed
that artesunate was able to potentiate the reduction of
Pf-iE development when combined with the F4 fraction,
indicating that these distinct compounds had a synergis-
tic effect. The fact that the interaction between F4 frac-
tion and artesunate did not exhibit antagonistic
interactions should prompt further exploration of novel
therapeutic concentrations and combinations of other
compounds from plants extracts for the treatment of
malaria. As studies of drug combinations may reduce
the risk of developing drug resistance and may lead to
more effective therapeutic regimens for the treatment of
malaria [44], a detailed evaluation of this synergic effect
in vivo will certainly bring to light pertinent issues such
as pharmacokinetics and pharmacodynamics of these
compounds, solely or combined.
Mass spectrometry analyses of the F4 fraction detected
an ion of m/z 303.0450, similar to the fragmentation pro-
file of quercetin (MM = 302), a natural flavonoid very
common in edible fruits and vegetables [46]. Indeed, pre-
vious studies on the composition of Caesalpinia spp. have
led to the isolation of several compounds, such as diter-
penes [47-49], flavonoids [50], biflavonoids [51] and tan-
nins [52]. Analyses of 480 plant-derived compounds have
revealed that diterpenoids and flavonoids isolated from
Caesalpiniaceae family are associated with anti-malarial
activity against P. falciparum [53]. However, a second set
of analyses using a quercetin standard showed distinct
ions of m/z 137 and 153. Furthermore, the IC50 value of
the F4 fraction (0.72 μg/mL) obtained in these work was
nine-fold lower than that of quercetin (6.5 μg/mL), as pre-
viously described [54], thus reinforcing the notion of a
new compound related to the anti-malarial activity of F4
fraction, both in vitro and in vivo assays.
Conclusion
The present study indicates that the F4 fraction of C.
pluviosa has no cytotoxic effect and exhibits anti-malar-
ial activity, both in vitro and in vivo. When combined
with artesunate, this fraction potentiated the activity by
significantly inhibiting parasitaemia. The presented find-
ings suggest that a new compound, most likely an iso-
mer of quercetin, is related to the anti-malarial activity
of the F4 fraction.
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